Who Owns Kura Oncology Stock?
NASDAQ: KURAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Ownership breakdown
- Held by institutions
- 100.08%
- Institutions (% of float)
- 101.50%
- Held by insiders
- 1.40%
- Institutional holders
- 303
- Institutions 98.6%
- Insiders 1.4%
- Public and other 0.0%
Who owns Kura Oncology stock?
Institutional investors own about 100.1% of Kura Oncology's shares, spread across 303 institutions that file 13F reports. That level of institutional ownership is high, typical of large, widely followed companies. Insiders, including executives, directors and large founding shareholders, hold 1.40% of KURA.
The largest institutional holders are Blackrock Inc. (11.81%), Montanova Capital LLC (9.64%) and BVF Inc. (9.49%). Together, the top 10 institutions control 56.5% of shares outstanding. In their latest filings, 7 of the top 10 institutions increased their KURA positions and 1 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of KURA
| Institution | Shares | % Held | Change |
|---|---|---|---|
| Blackrock Inc. | 10.51M | 11.81% | +9.0% |
| Montanova Capital LLC | 8.58M | 9.64% | 0.0% |
| BVF Inc. | 8.45M | 9.49% | 0.0% |
| State Street Corporation | 5.33M | 5.99% | +18.1% |
| Vanguard Capital Management LLC | 3.92M | 4.40% | +3.5% |
| Armistice Capital, LLC | 3.68M | 4.13% | -1.6% |
| AQR Capital Management, LLC | 3.13M | 3.51% | +47.2% |
| Goldman Sachs Group Inc | 2.27M | 2.55% | +58.0% |
| Geode Capital Management, LLC | 2.23M | 2.51% | +9.6% |
| Alethea Capital Management, LLC | 2.17M | 2.44% | +41.8% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of KURA
| Fund | Shares | % Held |
|---|---|---|
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 3.25M | 3.65% |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.80M | 3.15% |
| iShares Trust-iShares Russell 2000 ETF | 2.18M | 2.45% |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 1.03M | 1.15% |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 928.99K | 1.04% |
| iShares Trust-iShares Russell 2000 Growth ETF | 806.00K | 0.91% |
| iShares Trust-iShares Biotechnology ETF | 640.77K | 0.72% |
| BlackRock Funds-BlackRock Advantage Small Cap Core Fund | 564.98K | 0.64% |
| Fidelity Covington Trust-Fidelity Enhanced Small Cap Core ETF | 521.08K | 0.59% |
| Fidelity Concord Street Trust-Fidelity Extended Market Index Fund | 445.82K | 0.50% |
Frequently asked questions
Who is the largest shareholder of Kura Oncology?
Blackrock Inc. is the largest institutional shareholder of KURA, owning 11.81% of shares outstanding (10.51M shares) as of its latest 13F filing.
What percentage of Kura Oncology is owned by institutions?
Institutions own about 100.1% of KURA shares and 101.5% of the public float.
How much of Kura Oncology do insiders own?
Insiders, such as officers and directors, own about 1.40% of KURA shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.